重组人类促红细胞生成素(rhEP)应用于终末期肾脏病病人可改善贫血、相应的体力和生活质量,但有副作用。本文报道 rhEP 治疗对血压的影响。病人和方法伴贫血的血透病人被随机分为三组:①安慰剂组;②使用 rhEP 组,其剂量维持血红蛋白在95～110g/L;③rhEP 组,其剂量维持血红蛋白在115～130g/L。②及③组开始 Recombinant human erythropoietin (rhEP) used in patients with end stage renal disease can improve anemia, the corresponding physical and quality of life, but side effects. This article reports the effect of rhEP treatment on blood pressure. Patients and methods with anemia hemodialysis patients were randomly divided into three groups: ① placebo group; ② rhEP group, the dose to maintain hemoglobin in the 95 ~ 110g / L; ③ rhEP group, the dose of hemoglobin in the 115 ~ 130g / L . ② and ③ group began